The Interaction of lncRNA-HEIH and lncRNA-HULC with HBXIP in Hepatitis B Patients

Table 1

Clinical features of patients.

Parameter	Control	HBV	HBV + HC	HBV + HCC
Gender
Female	13	14	12	10	>0.05
Male	12	11	13	15
HBsAg
Negative	25	0	0	0	<0.05
Positive	0	25	25	25
Age	45.07 ± 15.06	40.18 ± 16.25	42.31 ± 8.56	45.62 ± 11.28	>0.05
ALP (U/L)	55.58 ± 12.01	91.46 ± 12.96	121.77 ± 16.89	157.29 ± 21.78	<0.05
ALB (g/L)	48.44 ± 8.88	43.32 ± 7.58	28.21 ± 6.69	30.37 ± 6.84	<0.05
TBIL (μmol/L)	15.23 ± 3.67	22.24 ± 4.52	33.52 ± 7.17	40.44 ± 8.03	<0.05
DBIL (μmol/L)	4.28 ± 1.13	8.44 ± 1.61	17.22 ± 3.35	27.24 ± 5.98	<0.05
AFP (μg/L)	4.95 ± 1.13	26.83 ± 4.67	52.79 ± 7.76	122.74 ± 18.76	<0.05
ALT (U/L)	25.48 ± 6.68	181.67 ± 21.90	69.28 ± 11.11	78.24 ± 10.94	<0.05
AST (U/L)	22.14 ± 5.11	196.75 ± 20.29	89.89 ± 13.22	102.25 ± 14.11	<0.05
HBV-DNA (copies/mL)	0	(7.12 ± 0.28) × 105	(2.23 ± 0.47) × 104	(7.35 ± 0.55) × 104	<0.05

HBsAg: hepatitis B surface antigen; ALP: alkaline phosphatase; ALB: albumin; TBIl: total bilirubin; DBIl: direct bilirubin; AFP: alpha-fetoprotein; ALT: alanine aminotransferase; AST: aspartate aminotransferase.